Abstract
Phospholipase A(2) (PLA(2)) is one of the major honey bee venom allergens for humans. To assess the long-term prevention of allergic reactions by DNA vaccination, a PLA(2)-CBA/J mouse model was employed using empty or PLA(2) sequence-carrying DNA plasmids. Early skin application of either DNA construct before (prophylactic approach) or after (therapeutic approach) sensitization with PLA(2)/alum led to reduced PLA(2)-specific IgE and IgG1 titers at 7 mo, with concomitant rise in IgG2a and IgG3. Splenocytes recovered at 5-6 mo after the last DNA administration exhibited a sustained IFN-gamma and IL-10 secretion and reduced IL-4 production. Recall challenge with PLA(2) boosted IFN-gamma and IL-10 secretion, suggesting the reactivation of quiescent memory Th1 lymphocytes. Mice from the prophylactic groups were fully protected against anaphylaxis, whereas 65% of the animals recovered in the therapeutic groups. Th1-polarized immune responses were also active in mice vaccinated with an empty plasmid 32 wk before sensitization with another Ag (OVA). This is the first demonstration that the Ag-coding sequence in DNA vaccine is not necessary to promote immune modulation in naive and sensitized animals for a prolonged period, and has relevance for the understanding of the innate and induced mechanisms underlying gene immunotherapy in long-term treatment of allergy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / genetics
-
Adjuvants, Immunologic / therapeutic use
-
Anaphylaxis / immunology
-
Anaphylaxis / prevention & control
-
Animals
-
Antibody Specificity / genetics
-
Antigens / administration & dosage
-
Antigens / physiology*
-
Bee Venoms / administration & dosage
-
Bee Venoms / immunology*
-
CHO Cells
-
Cells, Cultured
-
Cricetinae
-
Cytokines / biosynthesis
-
Cytokines / metabolism
-
Desensitization, Immunologic / methods*
-
Female
-
Genetic Vectors / administration & dosage
-
Genetic Vectors / immunology
-
Genetic Vectors / therapeutic use
-
Immunoglobulin E / biosynthesis
-
Immunoglobulin G / biosynthesis
-
Immunosuppressive Agents / administration & dosage*
-
Lymphocyte Activation / genetics
-
Mice
-
Mice, Inbred CBA
-
Ovalbumin / administration & dosage
-
Ovalbumin / immunology
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / genetics
-
Peptide Fragments / immunology
-
Phospholipases A / administration & dosage
-
Phospholipases A / genetics
-
Phospholipases A / immunology*
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
Th1 Cells / immunology
-
Th1 Cells / metabolism
-
Transfection
-
Up-Regulation / genetics
-
Up-Regulation / immunology
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / immunology*
-
Vaccines, DNA / therapeutic use
Substances
-
Adjuvants, Immunologic
-
Antigens
-
Bee Venoms
-
Cytokines
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Peptide Fragments
-
Vaccines, DNA
-
Immunoglobulin E
-
Ovalbumin
-
Phospholipases A